Fanconi AnemiaNCT07649031
MRI as Noninvasive Innovative Approach in Detection and Monitoring of Malignant Oral Lesions in Fanconi Anemia Patients
An observational study of Fanconi Anemia, run by University of Minnesota at 1 site in United States.
Trial summary
This study being done to learn more about the use of medical Magnetic Resonance Imaging (mMRI) and dedicated dental MRI (ddMRI) as a non-invasive diagnosing tool when evaluating potential oral cancerous and precancerous lesions in Fanconi Anemia patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fanconi Anemia
- What is being tested?
- MRIs
- How many people
- 80 participants
- Where
- 1 siteUnited States
- Study dates
- 23 Jun 2026to 31 May 2030
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with Fanconi anemia
Who may be able to join
- Patients with a diagnosis of Fanconi Anemia who are willing to participate and willing to have MRIs
- Willing to provide informed consent
Who cannot join
- Patient without diagnosis of FA
- Patients with FA who are under the age of 18
- Unable to tolerate any MRI due to claustrophobia
- Any contraindication for the MRI
- Unable to provide informed consent or comply with the study protocol
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Minnesota
Minneapolis, Minnesota, 55455
Carla Campbell, BS, 612-625-6976, camp2757@umn.edu
About this study
This study being done to learn more about the use of medical Magnetic Resonance Imaging (mMRI) and dedicated dental MRI (ddMRI) as a non-invasive diagnosing tool when evaluating potential oral cancerous and precancerous lesions in Fanconi Anemia patients.
- Conditions
- Fanconi Anemia
- Being tested
- MRIs
- Medical subject headings
- Fanconi Anemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRIsDiagnostic test
mMRI and ddMRI
| Study group | Role | What they receive |
|---|---|---|
| FA patients with a history of HNSCC | This group will receive both mMRI and ddMRI, with an exam, every 3-4 months for 2 years (up to 16 scan (+exam) visits). Receives: Diagnostic Test: MRIs | |
| FA patients with no history of HNSCC | This group will receive two scans each of mMRI and ddMRI, with an exam, one year apart (up to 4 scan (+exam) visits). Receives: Diagnostic Test: MRIs |
What is being measured
The primary outcome is the main question the study is designed to answer.
sensitivity of mMRI and ddMRI in identifying dysplastic and malignant lesions in FA patients.
Proportion of positive lesions correctly diagnosed
Measured: Immediately after MRI
specificity of mMRI and ddMRI in identifying dysplastic and malignant lesions in FA patients.
Proportion of negative lesions correctly diagnosed
Measured: Immediately after MRI
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2026
- Study start23 Jun 2026
- Primary completion31 May 2030 (estimated)
- Study completion31 May 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Fanconi AnemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Minnesota
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Rachel Uppgaard, Principal investigator, University of Minnesota
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07649031
- Sponsor's protocol ID
- DENT-2025-34242, STUDY00027283
- Status last verified
- Jun 2026
- First submitted
- 9 Jun 2026
- Last updated
- 2 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No